Japan Pharma market myths - by P Reed Maurer

Misinformation or myths about the Japan pharma market continue to restrict allocation of resources to either enter or expand a presence in the market, says P Reed Maurer, long-time Japanese pharma industry watcher and president of International Alliances Limited (IAL), in an exclusive article for The Pharma Letter.

This behavior results in huge opportunity costs because of the market size, growth, and lucrative pricing for innovative drugs.  There are many roads to success in Japan but endless studies of which road to take will never get you to an acceptable destination. “My objective here is to simply state what Japan insiders learned many years ago and now quietly reap substantial economic benefits from doing business in Japan versus to Japan,” says Mr Maurer.

Joint ventures do not work